KarXT for Psychosis in Alzheimer's Disease (ADEPT-3)
Overview
Mermaid diagram (expand to render)
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
The ADEPT-3 study (NCT05980949) is an open-label extension trial evaluating the long-term safety and tolerability of KarXT (xanomeline/trospium) in patients with psychosis associated with Alzheimer's disease. KarXT represents a novel approach to treating AD psychosis by targeting muscarinic receptors rather than dopamine receptors, potentially avoiding the side effects associated with conventional antipsychotics["@novel2024"].
Alzheimer's disease affects millions of individuals worldwide, and psychosis affects up to 50% of AD patients during the disease course, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of safe and effective treatments for behavioral symptoms, underscores the critical importance of clinical trials like this one in advancing our therapeutic options["@alzheimers2023"].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05980949 |
| Phase | PHASE3 |
| Status | RECRUITING |
| Sponsor | Karuna Therapeutics |
| Enrollment | 800 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2023-07-11 00:00:00 |
| Completion Date | 2027-09-07 00:00:00 |
| Last Updated | 2026-03-05 00:00:00 |
Conditions Studied
- Psychosis Associated With Alzheimer's Disease
Scientific Background
Disease Context
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].
Psychosis in Alzheimer's Disease
Psychosis affects 25-50% of AD patients and is associated with:
- More rapid cognitive decline
- Increased functional impairment
- Higher rates of institutionalization
- Greater caregiver burden
- Increased mortality risk
Current treatment options are limited and problematic:
- Atypical antipsychotics (risperidone, olanzapine, quetiapine) are commonly used but carry significant risks:
- Increased mortality (1.6-1.7x relative risk)
- Cerebrovascular events
- Extrapyramidal symptoms
- Cognitive worsening
- Metabolic syndrome
- Pimavanserin (Nuplazid) is FDA-approved for PD psychosis but not specifically for AD psychosis
- Non-pharmacological approaches have limited efficacy in moderate-to-severe psychosis
KarXT: A Novel Mechanism
KarXT is a fixed-dose combination of:
- Xanomeline: A muscarinic receptor agonist (M1/M4 preferential)
- Trospium: A peripheral muscarinic antagonist
Rationale:
Cholinergic deficit in AD: AD involves significant loss of cholinergic neurons, particularly in basal forebrain
Muscarinic receptor preservation: Despite neuronal loss, M1/M4 receptors remain relatively intact
Direct receptor activation: Agonizing remaining receptors may restore signaling
Peripheral blockade: Trospium prevents peripheral side effects (salivation, GI distress) of xanomelineAdvantages over conventional antipsychotics:
- Does not block dopamine D2 receptors (avoiding extrapyramidal symptoms)
- May improve cognition (M1 agonism)
- Does not cause metabolic disturbances
- May address cholinergic deficit underlying some behavioral symptoms
Clinical Development History
Phase 2 EMERALD Trial (Schizophrenia)[@emeraldtrial]:
- Demonstrated significant reduction in PANSS scores vs placebo
- Showed efficacy in both positive and negative symptoms
- Established safety profile in schizophrenia patients
ADEPT-1 and ADEPT-2 (Phase 2 in AD Psychosis):
- Demonstrated efficacy in treating psychosis symptoms
- Showed acceptable safety profile in AD population
- Led to Phase 3 program
ADEPT-3 (This Trial):
- Open-label extension to assess long-term safety
- Allows patients from Phase 2/3 trials to continue treatment
- Provides data on durability of response and long-term tolerability
Study Design
This is a Phase 3, open-label extension clinical trial designed to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's disease. Open-label extension studies allow participants to continue receiving the investigational treatment after completing the controlled phase, providing crucial long-term safety data[@clinical2023].
Key features of ADEPT-3 include:
- Open-label design: All participants receive active treatment
- Long-term follow-up: Up to 52 weeks of continuous treatment
- Real-world setting: Reflects typical clinical use
- Enrollment: 800 participants (estimated)
- Safety focus: Primary endpoint is adverse event monitoring
Participant Population
Participants eligible for ADEPT-3 include:
- Completers of ADEPT-1 or ADEPT-2 (Phase 2 trials in AD psychosis)
- Newly enrolled patients meeting inclusion criteria
- Age 55-90 years
- Clinical diagnosis of AD with psychosis
- MMSE score ≥10 (moderate dementia)
Treatment Regimen
| Parameter | Details |
|-----------|---------|
| Drug | KarXT (xanomeline/trospium) |
| Dose | Up to 100/60 mg BID |
| Route | Oral |
| Duration | 52 weeks |
| Frequency | Twice daily with food |
Outcome Measures
Primary Endpoints
- Incidence of treatment-emergent adverse events (TEAEs)
- Serious adverse events (SAEs)
- Discontinuations due to adverse events
Safety assessments include:
- Vital signs
- ECG
- Laboratory parameters (hematology, chemistry)
- Physical examination
- Adverse event monitoring
Secondary Endpoints
Efficacy maintenance:
- Change in NPI-Psychosis subscale score
- CGI-C (Clinical Global Impression of Change)
- Time to relapse
Cognitive effects:
- MMSE change from baseline
- ADAS-Cog change (in subset)
Functional measures:
- ADCS-ADL change
- Caregiver burden scales
Exploratory Endpoints
- Biomarker studies (in subset)
- Pharmacokinetic sampling
- Quality of life measures
Clinical Significance
This clinical trial represents a critical step in developing safe and effective treatments for psychosis in Alzheimer's disease[@future2024]:
Address unmet need: Up to 50% of AD patients develop psychosis; current treatments are inadequate and dangerous
Novel mechanism: KarXT targets cholinergic pathways rather than dopamine, potentially avoiding significant side effects
Long-term safety data: Essential for regulatory approval and clinical adoption
Improve quality of life: Reducing psychosis can decrease caregiver burden and delay institutionalization
Potential cognitive benefits: Unlike antipsychotics, KarXT may actually improve cognition through M1 agonismComparison with Current Treatments
| Treatment | Mechanism | Key Limitation |
|-----------|-----------|----------------|
| Risperidone | D2 antagonist | Increased mortality, EPS |
| Olanzapine | D2 antagonist | Metabolic syndrome, sedation |
| Quetiapine | D2 antagonist | Limited efficacy |
| Pimavanserin | 5-HT2A inverse agonist | Not approved for AD |
| KarXT | M1/M4 agonist | Long-term data pending |
Mechanistic Pathway: KarXT in AD Psychosis
Cholinergic Signaling and Cognitive Function
The cholinergic system plays a crucial role in memory and attention through two primary receptor subtypes: muscarinic (M1-M5) and nicotinic receptors. In Alzheimer's disease, the basal forebrain cholinergic neurons that project to the cortex and hippocampus are among the first to degenerate, leading to impaired acetylcholine transmission that contributes to both cognitive decline and behavioral symptoms[@novel2024].
M1 Receptors:
- Located primarily in the hippocampus and cortex
- Critical for memory formation and consolidation
- Coupled to Gq proteins and phospholipase C signaling
- Activation promotes phosphatidylinositol hydrolysis and calcium release
M4 Receptors:
- Located in the striatum and cortex
- Modulate dopamine release in mesolimbic pathways
- Coupled to Gi proteins that inhibit adenylate cyclase
- Activation reduces excessive dopaminergic activity
Muscarinic Agonism vs Antipsychotic Mechanisms
Traditional antipsychotics work primarily by blocking dopamine D2 receptors. While effective for hallucinations and delusions, this mechanism fails to address the cholinergic deficit in AD and often worsens cognition. The table below illustrates the fundamental difference:
| Property | Traditional Antipsychotics | KarXT (M1/M4 Agonist) |
|----------|-------------------------|---------------------|
| Primary target | D2 receptor | M1/M4 receptors |
| Cognitive effect | Often worsens | May improve |
| EPS risk | High | Low |
| Metabolic risk | High | Low |
| Dopamine modulation | Indirect reduction | Normalization |
The Xanomeline/Trospium Combination
The design of KarXT reflects sophisticated understanding of muscarinic pharmacology:
Xanomeline (M1/M4 Agonist) → Central nervous system
↓
[M1: Hippocampal memory enhancement]
[M4: Psychosis reduction via dopamine modulation]
↓
Trospium (Peripheral Antagonist) → Blocks peripheral side effects
↓
[No: Dry mouth, GI distress, bradycardia]
This combination allows xanomeline to exert beneficial central effects while preventing bothersome peripheral cholinergic side effects that would otherwise limit tolerability.
ClinicalEndpoints Deep Dive
Neuropsychiatric Inventory - Psychosis Subscale (NPI-Psychosis)
The NPI-Psychosis subscale specifically assesses:
- Hallucinations: Visual and auditory false perceptions
- Delusions: Fixed false beliefs (paranoia, misidentification)
- Agitation: Motor restlessness, verbal disruption
Each item is scored for:
- Frequency (1-4 scale)
- Severity (1-3 scale)
- Distress (0-5 scale provided by caregiver)
A reduction of ≥4 points is considered clinically meaningful.
CGI-C (Clinical Global Impression of Change)
The CGI-C provides global assessment of functional change:
- 1 = Very much improved
- 2 = Much improved
- 3 = Minimally improved
- 4 = No change
- 5 = Minimally worse
- 6 = Much worse
- 7 = Very much worse
In AD psychosis trials, CGI-C scores of 1-2 are considered positive responses.
Time to Relapse
Relapse is defined as:
- NPI-Psychosis score increase of ≥8 points from baseline
- CGI-C score of ≥4 (minimally worse)
- Requirement for rescue antipsychotic medication
- Hospitalization for behavioral emergency
Safety Profile
Adverse Event Profile
Common adverse events observed in KarXT clinical trials include:
| Adverse Event | Frequency | Management |
|-------------|----------|------------|
| Dry mouth | 25-30% | Sugar-free lozenges, hydration |
| Constipation | 15-20% | Laxatives, dietary fiber |
| Nausea | 10-15% | Take with food, antiemetics |
| Urinary retention | 5-10% | Monitoring, catheterization if severe |
| Hypertension | 5-8% | Antihypertensive adjustment |
Drug-Drug Interactions
KarXT may interact with:
- Anticholinergic medications: Additive effects
- Cholinesterase inhibitors: Additive cholinergic effects
- Beta-blockers: Potential bradycardia
- CYP2D6 substrates: Trospium is a weak inhibitor
Special Populations
Renal Impairment:
- Moderate impairment: Dose adjustment recommended
- Severe impairment: Not studied
Hepatic Impairment:
- Mild-moderate: No adjustment needed
- Severe: Not studied
Regulatory Status
FDA Approvals and Designations
KarXT has received:
- Fast Track Designation: For AD psychosis (2023)
- Breakthrough Therapy Designation: For schizophrenia (2019)
- NDA Submission: Submitted for schizophrenia (2024)
Comparison with Approved Psychosis Treatments
| Drug | Indication | Mechanism | FDA Status |
|------|-----------|-----------|-----------|
| Risperidone | PD/AD psychosis | D2 antagonist | Approved (with black box) |
| Olanzapine | AD psychosis | D2 antagonist | Approved (with black box) |
| Quetiapine | AD psychosis | D2 antagonist | Off-label |
| Pimavanserin | PD psychosis | 5-HT2A inverse agonist | Approved for PD only |
| KarXT | AD psychosis | M1/M4 agonist | Pending |
Post-Marketing Commitments
If approved, KarXT will require:
- Long-term safety monitoring
- Pediatric studies (if applicable)
- Risk evaluation and mitigation strategies (REMS)
Future Directions
Combination Approaches
Future trials may explore:
- KarXT + cholinesterase inhibitors
- KarXT + amyloid-targeting therapy
- KarXT + anti- tau immunotherapy
biomarkers for Patient Selection
Potential predictive biomarkers include:
- Basal forebrain volume (MRI)
- CSF cholinergic markers
- Muscarinic receptor density (PET)
- Transdermal patch delivery
- Extended-release formulation
- Fixed-dose combination with donepezil
Appendix: StudySites and Investigators
Participating Clinical Sites
The ADEPT-3 trial is conducted at multiple academic medical centers specializing in Alzheimer's disease and geriatric psychiatry. Sites are selected based on:
- Established AD research programs
- Experienced psychiatric and neurology faculty
- Access to neuroimaging and biomarker capabilities
- Diverse patient population access
Study Coordination
- Sponsor: Karuna Therapeutics (acquired by Bristol Myers Squibb)
- CRO: IQVIA or equivalent
- Data Management: Electronic data capture (EDC)
- Safety Monitoring: Independent DMC
Appendix: Regulatory History
Development Timeline
| Year | Milestone |
|------|-----------|
| 2019 | EMERALD Phase 2 (schizophrenia) positive results |
| 2021 | ADEPT-1 Phase 2 initiated |
| 2022 | ADEPT-2 Phase 2 results |
| 2023 | Phase 3 program initiated |
| 2024 | ADEPT-3 extension study initiated |
| 2025 | Expected NDA submission |
FDA Interactions
- Fast Track designation granted (2023)
- Breakthrough Therapy (schizophrenia, 2019)
- Type B meeting completed
- NDA filing expected 2025
- [Clinical Trials Overview](/clinical-trials/overview)
- [Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [KarXT for AD Psychosis](/clinical-trials/karxt-nct05511363-ad-psychosis)
- [Karuna Therapeutics](/companies/karuna-therapeutics)
- [Amyloid Beta](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
- [Muscarinic Receptors](/proteins/muscarinic-receptors)
- [Cholinergic System](/mechanisms/cholinergic-system)
- [AD Psychosis Pathway](/mechanisms/ad-psychosis)
External Links
- [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT05980949)
- [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT05980949)
- [Karuna Therapeutics](https://karunatx.com)
References
[Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)
[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)
[Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)
[Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)
[Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)
[Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)
[Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)
[Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)
[Karuna Therapeutics KarXT program (2023)](https://karunatx.com)
[EMERALD Trial: Xanomeline-Trospium for schizophrenia (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Prevalence and treatment of psychosis in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)Pathway Diagram
The following diagram shows the key molecular relationships involving nct05980949 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)